Soligenix Inc (SNGX) Stock Price, Quote & News

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 538 8200

Fax: 609 452 6467

Website: www.soligenix.com

Address:

29 Emmons Drive, Suite B-10, Princeton, United States

BillionerOfKing Sep. 16 at 12:32 PM

$SNGX trade update.

0 · Reply

Winning_calls Sep. 15 at 2:41 AM

$SNGX pick me up @ $2.91

0 · Reply

Sngxscam Sep. 14 at 12:39 PM

$SNGX look up the history of this company and its ceo schaber. its nothing but a pile of scam. all the tech is scrap heap garbage

1 · Reply

Sw1ngb0t Sep. 12 at 8:57 PM

$ORBS $INHD $APM $HWH $SNGX my precious

1 · Reply

Sw1ngb0t Sep. 10 at 9:22 PM

$NEGG $THAR (tag team) $APM $INHD $SNGX top five low float stocks with guaranteed targets that are gonna go fast. $APM is mid rip right now... missed it. $INHD is going to rip tomorrow guaranteed. tell me there are no guarantees and I'll block you!

1 · Reply

Nakuldesai Sep. 10 at 5:44 PM

$SNGX first sign of reversal.

0 · Reply

Sw1ngb0t Sep. 10 at 1:49 PM

$SNGX we got er dialed in now

0 · Reply

Sw1ngb0t Sep. 10 at 1:38 PM

$THAR $NEGG $APM $SNGX $INHD I really notice the market shifting this week. my screener went from 10 to 20 to 40 stocks the last few days

0 · Reply

Sw1ngb0t Sep. 9 at 9:31 PM

$SNGX closed above $2.66... that's a reverse imo

0 · Reply

Sw1ngb0t Sep. 9 at 9:12 PM

$THAR (all in) $NEGG $APM $SNGX $INHD... that's your get rich quick ETF right there... just make sure you don't overstay your welcome

0 · Reply

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 2, 2025, 7:30 AM EDT - 14 days ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 1:03 PM EDT - 4 weeks ago

Why Is Soligenix Stock Soaring On Monday?

Aug 18, 2025, 7:30 AM EDT - 4 weeks ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 14, 2025, 7:30 AM EDT - 4 weeks ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Aug 8, 2025, 8:30 AM EDT - 5 weeks ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Jul 31, 2025, 7:30 AM EDT - 6 weeks ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 8, 2025, 7:30 AM EDT - 2 months ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 1, 2025, 7:30 AM EDT - 2 months ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jun 6, 2025, 9:37 AM EDT - 3 months ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

May 9, 2025, 7:30 AM EDT - 4 months ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Apr 14, 2025, 7:30 AM EDT - 5 months ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Mar 25, 2025, 8:30 AM EDT - 6 months ago

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 7:30 AM EDT - 6 months ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 21, 2025, 7:30 AM EDT - 6 months ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 6, 2025, 7:30 AM EST - 6 months ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Feb 4, 2025, 7:30 AM EST - 8 months ago

Soligenix to Present at BIO CEO & Investor Conference

Jan 16, 2025, 7:30 AM EST - 8 months ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 8 months ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 9 months ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 10 months ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 10 months ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 10 months ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 10 months ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 11 months ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Oct 22, 2024, 7:30 AM EDT - 11 months ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 16, 2024, 7:30 AM EDT - 11 months ago

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 7, 2024, 7:30 AM EDT - 1 year ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Partnership with Sterling Pharma Solutions

Sep 20, 2024, 9:00 AM EDT - 1 year ago

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Aug 16, 2024, 9:00 AM EDT - 1 year ago

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

AREC

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

Jul 15, 2024, 10:16 AM EDT - 1 year ago

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 9, 2024, 12:46 PM EDT - 1 year ago

Soligenix stock rallies 400% on positive HyBryte trial results

Jul 9, 2024, 12:11 PM EDT - 1 year ago

Crude Oil Down 1%; Soligenix Shares Surge

Jul 9, 2024, 11:38 AM EDT - 1 year ago

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

Jun 14, 2024, 7:30 AM EDT - 1 year ago

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

Jun 7, 2024, 9:00 AM EDT - 1 year ago

Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

STSS

May 31, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Reverse Stock Split

May 29, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

May 24, 2024, 7:30 AM EDT - 1 year ago

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

May 23, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

May 21, 2024, 7:30 AM EDT - 1 year ago

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

May 20, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

May 16, 2024, 7:30 AM EDT - 1 year ago

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

May 10, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

BillionerOfKing Sep. 16 at 12:32 PM

$SNGX trade update.

0 · Reply

Winning_calls Sep. 15 at 2:41 AM

$SNGX pick me up @ $2.91

0 · Reply

Sngxscam Sep. 14 at 12:39 PM

$SNGX look up the history of this company and its ceo schaber. its nothing but a pile of scam. all the tech is scrap heap garbage

1 · Reply

Sw1ngb0t Sep. 12 at 8:57 PM

$ORBS $INHD $APM $HWH $SNGX my precious

1 · Reply

Sw1ngb0t Sep. 10 at 9:22 PM

1 · Reply

Nakuldesai Sep. 10 at 5:44 PM

$SNGX first sign of reversal.

0 · Reply

Sw1ngb0t Sep. 10 at 1:49 PM

$SNGX we got er dialed in now

0 · Reply

Sw1ngb0t Sep. 10 at 1:38 PM

$THAR $NEGG $APM $SNGX $INHD I really notice the market shifting this week. my screener went from 10 to 20 to 40 stocks the last few days

0 · Reply

Sw1ngb0t Sep. 9 at 9:31 PM

$SNGX closed above $2.66... that's a reverse imo

0 · Reply

Sw1ngb0t Sep. 9 at 9:12 PM

$THAR (all in) $NEGG $APM $SNGX $INHD... that's your get rich quick ETF right there... just make sure you don't overstay your welcome

0 · Reply

NetworkNewsWire Sep. 9 at 7:53 PM

Senior NIH Officials Allege Retaliation as Motive for Their Ouster $SNGX https://ibn.fm/2bjRO #biomedstocks #NIH

0 · Reply

NetworkNewsWire Sep. 9 at 7:34 PM

$SNGX Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation https://ibn.fm/HLXEx

0 · Reply

Sw1ngb0t Sep. 9 at 4:33 PM

$SNGX closes above $2.66 and that's a reversal

1 · Reply

Sw1ngb0t Sep. 8 at 9:59 PM

high value $THAR - I'm in at $3... gotta reverse now right??? $APM - nice reversal candle recently $NEGG - same thing $XAIR - something to watch $SNGX - let's see a reversal tomorrow

0 · Reply

HopehelpsU Sep. 8 at 9:38 PM

$SNGX So at $6 the bulls were screaming for more and claiming FDA approval when it was Orphan Drug Designation approval? $6 wasn't enough, $5 wasn't enough and 4s were where longs were "averaging down" ..... $3S were an insult, and now we're on our way back to $2.40, where there should be a decent dead cat bounce. GL

1 · Reply

Nakuldesai Sep. 8 at 9:20 PM

$SNGX dropping after hours too.

0 · Reply

cartiersockss Sep. 8 at 7:12 PM

$SNGX just keeps dropping..

0 · Reply

YouVSYou Sep. 8 at 5:44 PM

$NEON 80% ATR $SMX 35% $ZNB 29% $ABTC 27% $SNGX 26 Inside bar setups

2 · Reply

Bdtmandate Sep. 8 at 4:20 PM

$SNGX What’s up with this stock..?

0 · Reply

rock_stone Sep. 8 at 12:53 PM

$SNGX shorted heavily. margin raise don't sell you share to shorties.

0 · Reply

Sw1ngb0t Sep. 8 at 11:27 AM

H.C. Wainwright presentations: $BTAI - Today $APM - Wed $SNGX - Mon-Wed

0 · Reply

NVDAMillionaire Sep. 8 at 8:28 AM

$SNGX Brilliant piece that captures SNGX's situation perfectly. So if you want to update your understanding of SNGX or get to know SNGX better, this is essential reading. https://beyondspx.com/quote/SNGX/analysis/soligenix-breakthrough-potential-in-rare-diseases-and-vaccine-stability-nasdaq-sngx

0 · Reply

Market Cap	12.51M
Revenue (ttm)	120,000.00
Net Income (ttm)	-8.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,891.67%
Debt to Equity Ratio	0.00

Volume	129,400
Avg Vol	12,980,704
Day's Range	N/A - N/A
Shares Out	4.29M
Stochastic %K	53%
Beta	2.05
Analysts	Strong Buy
Price Target	$22.50